68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review

Lars J Petersen; Julie B Nielsen; Katja Dettmann; Rune V Fisker; Uwe Haberkorn; Louise Stenholt; Helle D Zacho

doi:10.3892/mco.2017.1280

⁶⁸Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review

Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho

Research output: Contribution to journal › Journal article › Research › peer-review

274 Downloads (Pure)

Abstract

Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with (18)F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, (68)Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.

Original language	English
Journal	Molecular and Clinical Oncology
Volume	7
Issue number	1
Pages (from-to)	67-72
Number of pages	6
ISSN	2049-9450
DOIs	https://doi.org/10.3892/mco.2017.1280
Publication status	Published - Jul 2017

Keywords

Journal Article

Access to Document

10.3892/mco.2017.1280

Final Published VersionFinal published version, 478 KB

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{80bc79504f8342bba95928e3b0eeadcb,

title = "68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review",

abstract = "Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with (18)F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, (68)Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.",

keywords = "Journal Article",

author = "Petersen, {Lars J} and Nielsen, {Julie B} and Katja Dettmann and Fisker, {Rune V} and Uwe Haberkorn and Louise Stenholt and Zacho, {Helle D}",

year = "2017",

month = jul,

doi = "10.3892/mco.2017.1280",

language = "English",

volume = "7",

pages = "67--72",

journal = "Molecular and Clinical Oncology",

issn = "2049-9450",

publisher = "Spandidos Publications",

number = "1",

}

⁶⁸Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. / Petersen, Lars J; Nielsen, Julie B; Dettmann, Katja et al.
In: Molecular and Clinical Oncology, Vol. 7, No. 1, 07.2017, p. 67-72.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - 68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml

T2 - Two case reports and a literature review

AU - Petersen, Lars J

AU - Nielsen, Julie B

AU - Dettmann, Katja

AU - Fisker, Rune V

AU - Haberkorn, Uwe

AU - Stenholt, Louise

AU - Zacho, Helle D

PY - 2017/7

Y1 - 2017/7

N2 - Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with (18)F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, (68)Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.

AB - Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with (18)F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, (68)Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.

KW - Journal Article

U2 - 10.3892/mco.2017.1280

DO - 10.3892/mco.2017.1280

M3 - Journal article

C2 - 28685078

SN - 2049-9450

VL - 7

SP - 67

EP - 72

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

IS - 1

ER -

68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review